Categories: News

Audax Private Equity Completes the Sale of Katena Products to Corza Medical, a GTCR Portfolio Company

BOSTON–(BUSINESS WIRE)–Audax Private Equity (“Audax”) today announced that it has successfully completed the sale of Katena Products (“Katena” or the “Company”) to Corza Medical (“Corza”), a GTCR portfolio company.

Katena is a leading global provider of precision ophthalmic instruments and therapeutics to physician offices, hospitals, surgical centers, distributors, medical device OEMs, and clinics. Founded in 1975 and headquartered in Parsippany, New Jersey, Katena’s product offering includes precision surgical instruments, single-use devices, and specialty biologics that are sold in over 110 countries through a network of direct salespeople and distributors. Katena has more than 200 employees across Europe and North America and serves over 5,000 customers around the world.

Since being acquired by Audax in 2015, Katena has undergone a period of transformation, growth, and success:

  • Invested in systems and IT infrastructure, including ERP and CRM systems upgrades, to support product quality, realize operational efficiencies, and drive sales
  • Expanded and improved manufacturing capabilities and infrastructure, including integration of supply chain with a continued focus on insourcing initiatives
  • Completed eight acquisitions in order to expand the Company’s product portfolio, geographic presence, and manufacturing capabilities

David Wong, Managing Director at Audax, said, “We’ve enjoyed a terrific partnership with the Katena team and are very proud of the growth the Company has achieved. Over the course of our investment, Katena has expanded both its product portfolio and customer base via organic growth and strategic acquisitions. We wish the team continued success as a part of Corza Medical with GTCR’s support.”

Steve Blazejewski, Chief Executive Officer of Katena, commented, “Audax has been an instrumental partner in helping Katena evolve into a leading ophthalmic products platform. With the support of Audax’ deep investment expertise, global resources, and operational experience, we have been able to accelerate our growth plans while enhancing our ability to meet the needs of our global customer base. We thank Audax for their partnership and look forward to embarking on our next phase of growth as a part of Corza Medical.”

Robert W. Baird & Co served as financial advisor and Kirkland & Ellis served as legal advisor to Katena.

About Audax Private Equity

Audax Group is a leading alternative investment manager with offices in Boston, New York, and San Francisco. Since its founding in 1999, the firm has raised over $30 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $7 billion in more than 140 platforms and over 1000 add-on companies, and is currently investing out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax Private Equity seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value. With more than 300 employees, Audax is a leading capital partner for North American middle market companies. For more information, visit the Audax Private Equity website: www.audaxprivateequity.com or follow us on LinkedIn.

About Katena Products

Katena Products, Inc., is an innovation-driven, medical technology company serving the global eye care community. Founded in 1975 as a premier provider of ophthalmic instruments for surgical and in-office applications, Katena has maintained its high-quality standards in ophthalmic instrumentation while expanding its product portfolio to include tissue biologics, diagnostic lenses, punctum plugs, and corneal transplant devices across cataract, glaucoma, and corneal surgery. Please visit our website https://www.katena.com/.

Contacts

For Audax:

Audax-SVC@SARDVERB.com
Sard Verbinnen & Co

Staff

Recent Posts

Back Pain, Prostatitis, Enlarged Prostate (BPH) and Kidney Stones are Treated with the Safest Thermobalancing Therapy

The first safe therapy with Dr Allen's Device has once again proved its ability to…

3 hours ago

Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

23 hours ago

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

1 day ago

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt…

1 day ago

Pramana Achieves Industry-Leading Milestone with Digital Pathology 2.0 Technology

Over 6.5 Million Glass Slides Digitized in the Last 12 Months and 15 Billion Images…

1 day ago